<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00861250</url>
  </required_header>
  <id_info>
    <org_study_id>R08096M</org_study_id>
    <secondary_id>2008-003936-38</secondary_id>
    <secondary_id>26866138MMY2063</secondary_id>
    <nct_id>NCT00861250</nct_id>
  </id_info>
  <brief_title>Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT</brief_title>
  <official_title>Assessment of Molecular Remission by ASO-RQ-PCR Technique After Induction Treatment With Bortezomib-dexamethasone (Vel/Dex) Followed by HDT With ASCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Hospital of Kanta-Hame</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seinajoki Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jyväskylä Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Päijänne Tavastia Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the rate of molecular remissions (MolR)
      assessed by ASO-RQ-PCR technique after induction treatment with bortezomib and dexamethasone
      (Vel/Dex) prior to high-dose therapy with melphalan and autologous stem cell transplantation
      (HDT-ASCT), and after HDT-ASCT in patients with multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HDT-ASCT is so far considered the standard of care for younger patients with multiple myeloma
      (MM). Current evidence indicates that quality of response is an important prognostic factor
      for long-term survival in MM. There are only very few data on molecular remissions (MolR)
      determined by the most sensitive technique, allele-specific-oligonucleotide - real-time
      quantitative - polymerase chain reaction (ASO-RQ-PCR) in MM, and there are no data available
      on molecular responses after bortezomib-based induction therapy followed by HDT-ASCT. The
      main aim of this study is to determine molecular response rate after ASCT following
      bortezomib-based induction treatment compared to a historical control group with conventional
      VAD induction treatment. A sensitivity of ASO-RQ-PCR technique will be compared to
      immunofixation and with immunophenotyping by flow cytometry.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Molecular remission after Vel/Dex induction (4 cycles) and 3-4 months after ASCT in those patients receiving CR or nCR</measure>
    <time_frame>Before ASCT and 3-4 months after ASCT and then with 3-4 months interval</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Vel/Dex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib + dexamethasone</intervention_name>
    <description>Bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4, 9-12 in cycles 1- 2, then bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4 in cycles 3-4, total number of cycles is 4, followed by HDT with ASCT</description>
    <arm_group_label>Vel/Dex</arm_group_label>
    <other_name>VelcadeTM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic multiple myeloma

          -  Age 18-65 years

          -  Written informed consent

        Exclusion Criteria:

          -  WHO performance status ≥ 2, unless related to MM

          -  Severe cardiac dysfunction

          -  History of hypotension

          -  Serious medical or psychiatric illness

          -  Severe hepatic dysfunction

          -  Severe polyneuropathy ≥ grade 2

          -  Active, uncontrolled infection

          -  Previously treated with chemotherapy or extensive radiotherapy for MM

          -  Known HIV positivity

          -  Severe renal dysfunction with need of dialyses

          -  History of active cancer during past 5 years, except non-melanoma skin cancer or stage
             0 cervical cancer

          -  Female patients who are pregnant or nursing

          -  Male or female patients of reproductive potential who are not practising effective
             means of contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raija H Silvennoinen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere University Hospital, Kuopio University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <state>Pirkanmaa</state>
        <zip>33 521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2009</study_first_submitted>
  <study_first_submitted_qc>March 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2009</study_first_posted>
  <last_update_submitted>June 15, 2016</last_update_submitted>
  <last_update_submitted_qc>June 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bortezomib plus dexamethasone induction therapy</keyword>
  <keyword>Autologous stem cell transplantation</keyword>
  <keyword>Molecular remission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/25303369</doc_url>
      <doc_comment>First study article: http://www.ncbi.nlm.nih.gov/pubmed/23206270</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

